Business Description
Founded in Shanghai in 2009, IMPACT Therapeutics discovers and develops targeted cancer drugs that work by exploiting specific weaknesses in tumor cells, a strategy known as synthetic lethality. Its lead product, Senaparib, is approved for treating ovarian cancer, while several other drug candidates are currently being tested in clinical trials for various advanced solid tumors. The company is also advancing a broader portfolio of early-stage compounds with the goal of expanding treatment options for cancer patients across China and beyond.
